|
Contact Us Harvard Medical School
Telephone 617-432-0442 |
|
Click |
NEWS ALERT
Harvard Medical School Office of Public Affairs
The Harvard Center for Neurodegeneration and Repair gets a new name
BOSTON, Mass. (October 2, 2007)—The Harvard Center for Neurodegeneration and Repair (HCNR) has a new name and tagline: Harvard NeuroDiscovery Center—collaborating to cure neurodegenerative disease. The goal of the name change is to help foster connections with people and organizations that share the Center’s vision to convert promising discoveries into effective treatments and cures for neurodegenerative disease.
Established in 2001 by Dr. Joseph B. Martin (Dean of Harvard Medical School, 1997 – 2007) and Dr. Dennis Selkoe (Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School and co-director of the Center for Neurologic Diseases in the Department of Neurology at Brigham and Women’s Hospital), the Harvard NeuroDiscovery Center pioneers biomedical research collaboration. Under the leadership of its Director, Adrian Ivinson, PhD, the focus of the Harvard NeuroDiscovery Center is to accelerate the development of new, effective treatments for neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, multiple sclerosis, amyotrophic lateral sclerosis (ALS) and Huntington’s.
By drawing on the intellectual strength and proven capability of the Harvard medical community and beyond, the Center drives a portfolio of innovative research collaborations, including its biotech-styled Laboratory for Drug Discovery in Neurodegeneration (LDDN) located in Cambridge, Mass. Fully equipped with advanced robotics and a 14-person industry-seasoned staff specializing in assay development and medicinal chemistry, the LDDN fills the critical "gap" between academia and biotech/pharma, helping to expedite the route from promising discoveries to real patient treatments.
The NeuroDiscovery Center also offers a variety of shared resources and technical expertise to its membership to support biomedical research as it relates to neurodegenerative disease. To date, the Harvard NeuroDiscovery Center has engaged over 600 researchers from across the Harvard medical community in a growing portfolio of outcome-directed research programs.
For more information about the Harvard NeuroDiscovery Center, visit the website at www.NeuroDiscovery.Harvard.edu.
CONTACTS:
OFFICE OF PUBLIC AFFAIRS:Alyssa Kneller
public_affairs@hms.harvard.edu
617.432.0442
HARVARD NEURODISCOVERY CENTER:
Patti A. Stoll, Deputy Director
patti_stoll@hms.harvard.edu
617.432.2800
Harvard Medical School has more than 7,000 full-time faculty working in eight academic departments based at the School's Boston quadrangle or in one of 47 academic departments at 17 Harvard teaching hospitals and research institutes. Those Harvard hospitals and research institutions include Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Cambridge Health Alliance, The CBR Institute for Biomedical Research, Children's Hospital Boston, Dana-Farber Cancer Institute, Forsyth Institute, Harvard Pilgrim Health Care, Joslin Diabetes Center, Judge Baker Children's Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Mount Auburn Hospital, Schepens Eye Research Institute, Spaulding Rehabilitation Hospital, VA Boston Healthcare System.